The STAT proteins (Signal Transducers and Activators of Transcription), were identi®ed in the last decade as transcription factors which were critical in mediating virtually all cytokine driven signaling. These proteins are latent in the cytoplasm and become activated through tyrosine phosphorylation which typically occurs through cytokine receptor associated kinases (JAKs) or growth factor receptor tyrosine kinases. Recently a number of non-receptor tyrosine kinases (for example src and abl) have been found to cause STAT phosphorylation. Phosphorylated STATs form homo-or hetero-dimers, enter the nucleus and working coordinately with other transcriptional co-activators or transcription factors lead to increased transcriptional initiation. In normal cells and in animals, ligand dependent activation of the STATs is a transient process, lasting for several minutes to several hours. In contrast, in many cancerous cell lines and tumors, where growth factor dysregulation is frequently at the heart of cellular transformation, the STAT proteins (in particular Stats 1, 3 and 5) are persistently tyrosine phosphorylated or activated. The importance of STAT activation to growth control in experiments using anti-sense molecules or dominant negative STAT protein encoding constructs performed in cell lines or studies in animals lacking speci®c STATs strongly indicate that STATs play an important role in controlling cell cycle progression and apoptosis. Stat1 plays an important role in growth arrest, in promoting apoptosis and is implicated as a tumor suppressor; while Stats 3 and 5 are involved in promoting cell cycle progression and cellular transformation and preventing apoptosis. Many questions remain including: (1) a better understanding of how the STAT proteins through association with other factors increase transcription initiation; (2) a more complete de®nition of the sets of genes which are activated by dierent STATs and (3) how these sets of activated genes dier as a function of cell type. Finally, in the context of many cancers, where STATs are frequently persistently activated, an understanding of the mechanisms leading to their constitutive activation and de®ning the potential importance of persistent STAT activation in human tumorigenesis remains.
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Introduction
Within a few years of the discovery in 1955 of interferon (Isaacs and Lindenmann, 1957) , the ®rst`c ytokine' to be discovered, the growth restraining properties of interferon preparations had been recognized (Baron et al., 1992; Paucker et al., 1962; Sokawa et al., 1977) . An avalanche of studies on what proved to be a series of secreted small proteins followed in the 1960's and 1970's. The major basis for recognition and de®nition of these extracellular factors was their ability to induce dierentiation and progression to maturity of dierent speci®c blood cell precursors (Metcalf, 1989) . Growth regulation as viewed in the 1990's context, i.e. controlling crucial molecular events in the cell cycle was, of course, not possible in the early stages of cytokine studies, but the eects of cytokines on overall cell growth were also important in their original recognition. For example, IL-2 was discovered and eventually puri®ed as a substance that allowed the establishment of T cells in continuous culture (Arya and Gallo, 1985; Arya et al., 1984) , the basic breakthrough that allowed recognition of the AIDS virus. Among the early results relating cytokines directly to growth control was the demonstration that interferon slowed the entry of cultured cells from late G1 into the S phase and thus slowed cell growth rates (Balkwill and Taylor-Papadimitriou, 1978; Baron et al., 1992; Lin et al., 1986) .
The molecular dissection of pathways through which extracellular cytokines act on intracellular molecules succeeded in the 1980's and early 1990's ®rst by identifying cytokine receptors and then through molecular cloning obtaining their amino acid sequences (Ihle 1995; Kishimoto et al., 1994) . Second, the genes were cloned for intracellular proteins through which signals are passed from the liganded receptor to the cell nucleus. These transcription factors change cell behavior through transcriptional regulation. The ®rst such pathway to be unearthed in detail was IFN signaling through receptor associated JAK tyrosine kinases to the latent cytoplasmic transcription factors eventually termed STATs, for signal transducers and activators of transcription (Darnell, 1997; Darnell et al., 1994; Stark et al., 1998) . The tyrosine phosphorylated STATs dimerize and accumulate in the nucleus where occupation of speci®c DNA binding sites results in increased transcription. Inevitably the role in growth control of the STAT molecules, now numbering seven identi®ed proteins (Stats 1, 2, 3, 4, 5A, 5B and 6) activated by more than 40 dierent polypeptides became a central issue in cytokine research. In fact, since the discovery of the STATs as targets of cytokine activation, it was recognized in 1993 that the STATs can also be activated in response tò growth factors' such as EGF and PDGF and other related ligands through the intrinsic tyrosine kinases of the cognate receptors. Most recently still other Oncogene (2000) 19, 2468 ± 2473 ã 2000 Macmillan Publishers Ltd All rights reserved 0950 ± 9232/00 $15.00 www.nature.com/onc *Correspondence: JE Darnell Jr routes of STAT activation have been reported such as G-protein signaling and angiotensin binding to its 7-transmembrane receptor probably through Jak kinase activation (Marrero et al., 1995; Vila-Coro et al., 1999; Wong and Fish, 1998) .
While this report will concentrate on the role of Stat1 and Stat3 in growth regulation, it will be useful ®rst to summarize the functional molecular anatomy of the STATs and their interaction with other proteins as they function in transcriptional control (Figure 1a, b) . It is generally assumed that the biologic eects of the STATs depend on the genes acted upon by these activated transcription factors.
The complexity of eukaryotic transcriptional initiation and its regulation
Recent advances in the transcription ®eld have occurred across a broad front implicating over 100 proteins that serve in recruiting polymerase II to a start site (Gu et al., 1999; Holstege and Young, 1999) . A review of this vast subject is not possible here. But we note simply that the multi-subunit polymerase II is accompanied at a start site by a regular set of general transcription factors (GTFs), and that initiation sites in chromatin covered templates must, probably in most cases, be exposed by chromatin remodeling factors including histone acetyl transferases (HATs). Finally the activating proteins like the STATs probably most often bind not alone, but in combination with other site speci®c and more general DNA binding proteins in coordinated groups of proteins termed enhanceosomes (Carey, 1998) . The activating proteins in the enhanceosomes are crucial to eect changes in the rates of initiation and they do this by acting through still other sets of proteins called coactivators of which a complex termed mediator (Gu et al., 1999; Holstege and Young, 1999) may be the most often used class but which also include the TATA box binding factor TBP and the TBP associated factors, the TAFs (Berk, 1999) .
The positive acting proteins in an enhanceosome, working coordinately, interact with the co-activators and the chromatin remodeling proteins to cause increased transcriptional initiation. One important current area of research with the STATs is to discern the parts of the STATs that interact with either (and/ or) other transcription factors or the various newly discovered protein complexes to trigger transcription initiation. Interaction sites between STATs and these other proteins can then be tested for functional requirements in transfection experiments in vivo and they can ultimately be tested in vitro.
STAT domains: structure and function
From the three-dimensional structure of DNA bound dimers of the core of Stats 1 and 3, several regular domains of the proteins are obvious (Figure 1a,b) . Beginning around residue 130 there are four long helical coils in which interactions with other proteins occur. Residues *300 ± 500 comprise the DNA binding domain, a region of beta-sheet structures connected by unstructured loops. A linker domain from *500 ± 575 that is all alpha helical followed by a classical 7SH2 domain. Reciprocal pY-SH2 interactions hold the dimer together so that DNA contacts on the dyad symmetrical binding site can occur. (Missing from the core structure is the amino terminal domain and the 7COOH terminal domain.) The regions that have been implicated in transcription activation are the 7COOH terminal 38 amino acids of Stat1 and the terminal *75 amino acids of Stat3. Included in the COOH terminal region of Stats 1 and 3 is a critical S (727 in both proteins) and a critical L residue (724 in Stat1) (Wen et al., 1995; Zhang et al., 1998) . Interaction of this 7COOH terminal region from both Stat1 and 2 with histone transacetylases has been established (Bhattacharya et al., 1996; Horvai et al., 1997; Zhang et al., 1996) . In addition, and dependent on serine phosphorylation, the Stat1 7COOH terminus interacts with MCM proteins (Zhang et al., 1998) . The MCM proteins are known to be important in initiating DNA replication origins, but their role in RNA synthesis is unknown. While all of the STAT molecules depend on this 7COOH terminal segment for transcriptional activation, other regions of the STAT molecule also contribute to transcriptional activation. The NH 2 terminus is required in transcription as judged by defective stimulation in transfection experiments of NH 2 terminal deletions (Meraz et al., 1996) . Also there is known interaction with histone transacetylases (CBP/ p300 proteins) by the 7NH 2 terminal end of Stat1 which may contribute to transcription activation (Horvai et al., 1997; Zhang et al., 1996) . In addition many natural STAT binding sites (and in fact the most frequently used transfection target) contain closely spaced tandem STAT binding sites (Darnell, 1997; Guyer et al., 1995) . When two such sites are occupied there is STAT dimer ± dimer interaction mediated by the N-terminus (Xu et al., 1996) and this has proved to be necessary for maximal transcriptional stimulation, especially clearly for Stat5 (John et al., 1999) .
Finally, mutations in the linker domain of Stat1 (connecting the DNA binding domain with the 7SH2 domain) led to a protein that can be phosphorylated on tyrosine, dimerize, accumulate in the nucleus and bind DNA but fail completely to activate transcription (Yang et al., 1999) .
In addition to these studies which presumably give hints about how STATs themselves engage the transcriptional machinery, there is considerable evidence of STAT interactions with other transcription factors bound to neighboring sites in upstream segments of the DNA of various genes. Thus, Stat1 and Sp1 interact on the ICAM promoter (Look et al., 1995) , Stat5 and the glucocorticoid receptor interact on the b casein promoter (Stocklin et al., 1996) , Stat5 and CEBP on the immunoglobulin heavy chain germline epsilon promoter (Delphin and Stavnezer, 1995) , Stat3 and c-Jun interact on the a2 macroglobulin promoter ) and a host of other genes have been found to have closely spaced required DNA binding sites for a STAT protein and some other transcription factor (Guyer et al., 1995; Look et al., 1995; Xu et al., 1996) . These enhancesome interactions in the STAT family of proteins promise to be of great importance as they are known to be in b IFN promoter (Kim and Maniatis, 1997; Thanos and Maniatis, 1995) and in the promoter for the alpha chain of T cell receptor (Giese et al., 1995) .
Against this brief background on the structurefunction relationship of STAT domains we now want to consider the biologic roles of the STATs in growth control.
Stat1 in growth restraint
The slower growth of cultured cells after IFN treatment was established many years ago (Einat et al., 1985a,b) and depends upon fully transcriptionally activated Stat1 (Bromberg et al., 1996) . Recently Stat1 null mice have added immense support for a growth restraining role of Stat1 in the whole animal (Durbin et al., 1996; Meraz et al., 1996) . First, Stat1 7/7 animals develop tumors in response to lower doses of methylcholanthrene treatment than do normal mice (Kaplan et al., 1998) . Furthermore, coupling the Stat1
genotype with removal of the tumor suppressor gene, p53, leads to greatly enhanced spontaneous mouse tumor formation. Finally, the cells in a number of human tumor samples show a defective response in activation of Stat1 by IFN-g and fail to slow growth in culture as a result. Thus it appears that an IFN-g mediated Stat1 dependent tumor surveillance system is at work in mice. Tumor occurrence is suppressed by this system and estab-lished tumors can escape suppression by avoiding the growth restraint imposed by IFN-g.
Further results about growth restraint due to Stat1 have been described. In mutant chondroblasts, where the FGF receptor is constitutively activated, persistent activation of Stat1 is observed and profound growth arrest associated with the activation of the Cdk inhibitor, p21 (Sahni et al., 1999; Su et al., 1997) . Furthermore, in A431 cells, growth inhibition by EGF correlates with Stat1 but not Stat3 activation (Bromberg et al., 1998a) . Thus, there is mounting evidence that Stat1 activation frequently provides an antiproliferative eect and may partially explain why the lack of this molecule in vivo leads to increased tumor formation.
Tumor formation may of course require a constant growth stimulus but also cells that are accumulating mutations, as is typical of cancer cells, must also escape apoptosis. Stat1 in a number of cell types of this kind promotes apoptosis (Chin et al., 1997; Kumar et al., 1997) and its removal could also promote tumor cell survival and establishment of tumors.
Possible roles of Stats 3 and 5 in human oncogenesis
For several years reports have accumulated showing clinical tumor samples contain activated Stat 3 and 5 proteins without known ligand stimulation. Some of the best studied cases in this connection is persistent Stat3 activation in squamous cell head and neck cancer (discussed by J Grandis in this volume) and in multiple myeloma (discussed by R Jove in this volume). The basis for constitutive activation of Stat3 in the case of squamous cell carcinoma is due to aberrant EGF signaling. However in most of the other clinically reported cases of persistent activation of Stat3 the cause is not known.
In cell culture Stat3 was shown to be persistently activated (tyrosine phosphorylated; and capable of binding DNA) in all src transformed cell lines (Yu et al., 1995) . This ®nding set the stage for determining whether Stat3 activation was a necessary part of transformation in culture or merely an accompaniment. Both in our laboratory (Bromberg et al., 1998b) and R Jove's group (Turkson et al., 1998) using dominant negative Stat3 molecules, it was found that in vitro transformation by src required Stat3 activation.
To test the potency of Stat3 as a sole transforming agent, we engineered a constitutively active Stat3 molecule (Stat3-C; constitutive dimerization was achieved through cysteines inserted in the 7SH2 region) (Bromberg et al., 1999) . This molecule spontaneously dimerizes and accumulates in the nucleus where it can bind DNA and drive transcription. As a result, mouse and rat cells in culture can be transformed and the resulting transformed cells are capable of forming tumors in nude mice. Thus by uniting the mounting clinical evidence with the cell culture evidence it appears highly likely that Stat3 regularly participates in human tumors. In general, Stat3 activation has been associated with proliferation, anti-apoptosis and cellular transformation. However, there are a number of examples where activated Stat3 appears to play a role in dierentiation and promoting apoptosis (Chapman et al., 1999; Minami et al., 1996; Nakajima et al., 1996; O'Farrell et al., 1998) . These observations are not necessarily surprising given the evidence that proteins (for example myc) which control cell proliferation are tightly linked to those that drive cell death (Evan and Littlewood, 1998; Hueber and Evan, 1998 ).
An interesting possible connection between Stat3 and tumorigenesis is its association with c-Jun , the ®rst discovered nuclear protooncogene (Maki et al., 1987) . The c-Jun interaction does not occur with Stat1. Furthermore, there are a number of enhancer elements that contain c-Jun and Stat3 sites but no reported cases of genes driven by Stat1 and cJun.
Stat5 also appears on the basis of cell culture, animal and clinical results to be involved in tumorigenesis, apoptosis and cell proliferation. For example, a number of oncogenes such as the BCR/ABL tyrosine kinase and HTLV-1 leads to persistent tyrosine phosphorylation of Stat5 (Migone et al., 1995; Shuai et al., 1996) ; and a Stat5 dominant negative protein in murine bone marrow cultures can abrogate cellular transformation by BCR/ABL (Nieborowska- Skorska et al., 1999) . A constitutively activated form of Stat5 can obviate IL-3 dependent growth in the pro-B cell line (BaF3) yet when the mutant protein is hyper-activated by a ligand it induces apoptosis (Onishi et al., 1998) through abnormally sustained transcriptional activation of the Jak inhibitors JAB/SOCS-1/SSI-1 (Nosaka et al., 1999) . Furthermore, activated Stat5 can promote cell cycle progression in T cells (Moriggl et al., 1999) and protects certain cell types from apoptosis possibly through upregulation of Bcl-xL (Socolovsky et al., 1999) .
Conclusion
Studies of STAT molecules continue to reveal information both about how these proteins participate in triggering transcription and about the biologic eects of their activation. At this time it seems safe to conclude that Stat1 plays a role in growth restraint while both Stat3 and Stat5 are important to unrestrained growth of many human tumors. Both molecules may play a role in propelling at least speci®c cells through the cell cycle but it seems most clear that they also play anti-apoptotic roles.
One speculation that has been raised is stimulated by the frequent co-activation of Stat1 and 3 by the same ligand and the frequently observed Stat1 : 3 heterodimer. Perhaps these ®ndings point to a usual balancing eect of Stat1 and Stat3 on each other. Examination of downstream genes controlled by each and the eect of both active simultaneously will be important in evaluating such a possibility.
Given the evidence that a persistently activated Stat3 molecule is both necessary and sucient for cellular transformation and that STATs are frequently constitutively activated in a variety of cancers, it is now imperative to determine how persistent activation is achieved (and maintained) and to search for how persistent activation plays a role in the transformed phenotype.
